LTRN Insider Trading Activity and SEC Form 4 Filings
LTRN insider trading summary
Over the past 12 months, insiders at Lantern Pharma Inc. (LTRN) reported 2 open-market purchases worth $200K by 2 insiders and no sales on SEC Form 4. Net insider buying was $200K.
Latest LTRN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 12, 2026 | Lee Troy Schalop | Director | Buy | $100K (48,544 @ $2.06) |
| May 12, 2026 | D Jeffrey Keyser | Director | Buy | $100K (48,544 @ $2.06) |
| Jun 13, 2025 | BIOS Fund II QP, LP | 10% Owner | Sell | $22K (7,206 @ $3.09) |
| Jun 13, 2025 | BIOS Fund I, LP | 10% Owner | Sell | $22K (7,206 @ $3.09) |
| Jun 13, 2025 | Bios Equity Partners, LP | 10% Owner | Sell | $22K (7,206 @ $3.09) |
| Jun 13, 2025 | BIOS Fund II, LP | 10% Owner | Sell | $22K (7,206 @ $3.09) |
| Jun 13, 2025 | BIOS Fund I QP, LP | 10% Owner | Sell | $38K (12,319 @ $3.09) |
| Jun 13, 2025 | BIOS Fund I QP, LP | 10% Owner | Sell | $22K (7,206 @ $3.09) |
| Jun 13, 2025 | Aaron G.L. Fletcher | 10% Owner | Sell | $22K (7,206 @ $3.09) |
| Jun 13, 2025 | Bios Equity Partners II, LP | 10% Owner | Sell | $22K (7,206 @ $3.09) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.